Being Fitter May Help Your Kidneys Age More Slowly, New Study Finds

Image
Your fitness level today could be a clue to how well your kidneys age. A new study from Japan has found that adults with higher cardiorespiratory fitness experienced a slower decline in kidney function over five years — suggesting that staying fit may help protect the kidneys long before any disease appears. The research, published in the November 2026 issue of Medicine & Science in Sports & Exercise, followed 198 adults with healthy kidney function, with a median age of 61.4 years. The team from the University of Tsukuba, led by Shun Yoshikoshi, measured each participant's cardiorespiratory fitness — the body's ability to supply oxygen during sustained activity — using a submaximal cycling test, then tracked their kidney function annually for five years. The results were clear: participants with higher fitness showed a slower decline in kidney function when it was estimated using cystatin C, a blood marker of how efficiently the kidneys filter waste. The link held even...

FDA Orders New Eye Warning on Ozempic, Wegovy and All GLP-1 Drugs Over Rare Vision Risk


The U.S. Food and Drug Administration has ordered a new safety warning on every GLP-1 weight-loss and diabetes drug sold in the United States, after identifying a potential increased risk of a rare eye condition that can cause sudden vision loss.

In a Drug Safety Communication issued on November 9, 2026, the FDA said it is requiring manufacturers of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to add information about non-arteritic anterior ischemic optic neuropathy, or NAION, to the Warnings and Precautions section of their product labels.

NAION, often described as an "eye stroke," is caused by reduced blood flow to the optic nerve. It can cause sudden, painless vision loss in one eye, including blind spots, tunnel vision or distorted colours, and the damage is usually not reversible.

The warning covers the full GLP-1 class, including Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), Saxenda and Victoza (liraglutide), and Trulicity (dulaglutide). The FDA said cases of NAION have been reported with all currently marketed GLP-1 drugs.

The decision followed an extensive review of clinical trial data, animal studies, adverse-event reports and observational research. In a meta-analysis of 126 randomised trials covering 134,253 patients, researchers identified 15 probable NAION cases: 10 among people taking GLP-1 medicines and 5 among those receiving comparator treatments. That works out to 6.4 cases per 100,000 person-years on GLP-1 drugs, versus 3.8 in the comparison groups.

The FDA stressed that the risk is rare and potential, not proven — the agency has not concluded that the medicines cause NAION. It has also not advised patients to stop treatment. Instead, the FDA advises anyone taking a GLP-1 drug who notices sudden, painless changes in vision to contact a healthcare professional immediately. Risk factors for NAION include diabetes, high blood pressure, smoking, sleep apnoea, anaemia and kidney disease.

Europe moved first on one drug: in June 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide.

Millions of Americans now take GLP-1 medicines, so even a rare risk matters. If you take one of these drugs, know the warning signs — and do not ignore a sudden change in your vision.

This article is for information only and is not medical advice. Talk to your doctor about any concerns.

Sources: U.S. Food and Drug Administration, Firstpost, Pharmaceutical Executive

Photo credit: Best Life

Comments

Popular posts from this blog

Eating Less Protein Could Slow Aging, Major Review of 350 Studies Suggests

Build Muscle, Beat Diabetes: Why Strength Training Is a Powerful Tool for Blood Sugar Control This World Diabetes Day

Your Waist Size May Matter More Than Your Weight, Massive Study of 17 Million Adults Finds